SciClone Shareholder Settlement Suggests New Trend in FCPA Derivative Suits
SciClone Pharmaceuticals Inc.’s Dec. 15 settlement with shareholders in a Foreign Corrupt Practices Act derivative suit may mark a new focus on corporate governance initiatives as plaintiff lawyers seek quick-hit legal fees.
To read more
Subscribe to Global Investigations Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Investigations Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10